MMJ Recs

MAY 9, 2024

In this instance, medical cannabis offers a promising alternative or complementary treatment option. For veterans considering medical marijuana as a treatment option, it’s essential to approach its usage with careful consideration and understanding. Image by National Cancer Institute on Unsplash.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

MMJ Recs

NOVEMBER 20, 2023

These two cannabinoids represent just a fraction of the compounds within the cannabis plant, and ongoing research continues to uncover the potential of other lesser-known cannabinoids. Therapeutic Effects of Cannabinoids Pain Relief: Perhaps one of the most recognized therapeutic effects of cannabinoids is pain relief.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

AUGUST 26, 2022

Several companies are facilitating the development of this product. More research is still needed to explore this uncharted territory. CBD has been suggested to act as a treatment for sclerosis symptoms, as well as epilepsy among children. However, deeper research is needed to better understand its roles. Flashing lights.

Epilepsy 52

Epilepsy Treatment CBD Sleep 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JANUARY 12, 2022

The sale will accelerate the development of Gb Sciences’ proprietary Parkinson’s disease and COVID-related Cytokine-Release Syndrome therapies. “We have emerged from this sale as a pure-play biopharmaceutical research and development company. LAS VEGAS, Jan. 11, 2022 (GLOBE NEWSWIRE) — Gb Sciences, Inc.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. It’s an interesting analysis of who is using which strains to help treat which types of pain. RYAH Group Inc. The Upshot.

Data 105

Data Clinical Trials Research and Development Indica 105

Veriheal

MAY 3, 2022

A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research. Clinical Trial Sample Size.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

OCTOBER 17, 2019

(Tree of Knowledge) (CSE:TOKI) (OTC:TOKIF) expands global medical marijuana and CBD research in partnership with the Caribbean Institute of Pharmacy Policy (CIPPPAR) in Jamaica. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

JUNE 8, 2021

OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has entered into a Scientific Research Agreement (SRA) with the University of California San Francisco (UCSF). Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

The Cannigma

MAY 1, 2023

Previously thought of as either a horse tranquilizer or a dissociative recreational party drug, ketamine has re-emerged as a promising therapeutic agent to treat pain, PTSD, depression, anxiety and more. Ketamine was approved by the FDA in 1970 and was immediately put to use as an important tool for war medics in the Vietnam War.

Blood Pressure 80

Blood Pressure Chronic Pain Research and Development Clinical Trials 80

Cannabis Law Report

SEPTEMBER 6, 2021

Cannabis is safer and has less severe side effects in comparison to other treatment options. It also finds usage along with other treatments either to enhance their efficacy or to combat adverse side effects. 12 Overview of Clinical Research Suggesting the Benefits of Medical Cannabis Across Various Indications.

Chronic Pain 86

Chronic Pain Research and Development Clinical Trials Epilepsy 86

MMJ Recs

DECEMBER 22, 2023

Historically, marijuana was vilified and classified as a Schedule I controlled substance, which hindered both research and public acceptance. The AIDS epidemic in the 1980s brought attention to the potential benefits of marijuana in alleviating symptoms such as nausea and appetite loss associated with the disease and its treatment.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

NOVEMBER 24, 2019

Recommendations for research. Chronic pain. Severe treatment-resistant epilepsy. Consider nabilone as an add-on treatment for adults (18 years and over) with chemotherapy-induced nausea and vomiting which persists with optimised conventional antiemetics. Chronic pain. Recommendations. Spasticity.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Psychedelic therapy is not a fringe phenomenon.

Law 105

Law Therapy Clinical Trials Research and Development 105

CannaTech

MARCH 24, 2019

Medical cannabis is making its way out of the haze and into the headlines as expanded research programs demonstrate its proven benefits. Some of the most recognized applications of cannabinoid-based medicine are in the treatment of neuropathic pain , inflammation and muscle spasticity. However, this is slowly changing.

Research and Development 45

Research and Development Therapy Clinical Trials Chronic Pain 45

SpeedWeed

AUGUST 4, 2021

After watching my brother self-medicate for his chronic pain for decades, I didn’t understand how cannabis was important to him as a medicine. I always thought he used his chronic pain as an “excuse” to self-administer what I thought was a toxic drug. . in 2014, I watched my brother walk into a cannabis clinic.

Chronic Pain 52

Chronic Pain Research and Development Medicine Supply Chain 52

Cannabis Law Report

NOVEMBER 16, 2021

Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. “For MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-?

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

DECEMBER 28, 2021

The users of CBD products claim to have seen improvement in different medical conditions, including depression, chronic pain, insomnia, epilepsy, anxiety, etc., Moreover, the FDA has also allowed researchers to conduct CBD trials. But things have changed after FDA eased out regulations in 2015 to carry out CBD trials.

CBD 52

CBD Clinical Trials Consumption Chronic Pain 52

Cannabis Law Report

OCTOBER 26, 2021

MyMD’s lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheumatoid arthritis. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Dr. Chapman Bio.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

The Cannigma

DECEMBER 12, 2022

Now, psychedelic research is booming. And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders. 19 20 21 22 23.

History 119

History Microdosing Research and Development Clinical Trials 119

The Cannigma

SEPTEMBER 21, 2021

Dubbed by SFGate “The Coach Who Rolls the Best Blunts in the NBA,” Golden State Warriors Coach Steve Kerr has admitted to using marijuana to cope with nagging back pain. But it was worth it, because I’m searching for answers on pain. But Tommy Chong’s use of cannabis as a personal medical treatment is far less widely known.

Patients 94

Patients Research and Development Sleep Clinical Trials 94

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

The Cannigma

JUNE 24, 2021

Research has found that meditation can potentially have a variety of health benefits , including lowering blood pressure, reducing anxiety and depression, and may even provide some relief from conditions like irritable bowel syndrome and ulcerative colitis. Meditation and mindfulness. Cannabinoids may ease nausea and vomiting.

CBD 75

CBD Microdosing Edibles Sleep 75

Cannabis Law Report

APRIL 10, 2019

These include “to initiate a process evaluation to address barriers” and to ask “the National Institute for Health Research and the industry to take action to produce … evidence in a form that will support decisions about public funding.”.

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

Cannabis Law Report

JULY 15, 2019

ACM takes in consideration the characteristics of medical cannabis preparations and substances, and is a simplified version of the marketing authorization required for medicinal products to some extent (for instance, no clinical trials are required). Regardless all these regulatory developments, what did change, in fact?

Medicine 40

Medicine Clinical Trials Patients Access 40

Cannabis Law Report

JUNE 9, 2022

We understand the number of people who will need medical treatment due to this exposure. The bill aims to improve the quality of medical services for the population that undergoes palliative medicine and encourage medical research on cannabis. Activities for the development of new narcotic drugs or psychotropic substances.

Seed-To-Sale 52

Seed-To-Sale Legalization Cultivation Medicine 52

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

OCTOBER 22, 2021

The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronic pain, cancer, arthritis, diabetes, depression, anxiety, and many more. BX-1: Bionorica SE BX-1 is an oral solution containing dronabinol, being developed by Bionorica.

Research and Development 52

Research and Development Pharmaceutical Marijuana Chronic Pain 52

Cannabis Law Report

OCTOBER 6, 2021

Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (“IND”) for AnQlar, as required by the U.S. Food and Drug Administration (“FDA”).

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

SEPTEMBER 20, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, has acquired the exclusive worldwide rights from Nanomerics Ltd. –Virpax to Expand Use of Molecular Envelope Platform Technology– BERWYN, Pa.–(BUSINESS

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 18, 2021

The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronic pain, cancer, arthritis, diabetes, depression, anxiety, and many more. BX-1 is an oral solution containing dronabinol, being developed by Bionorica. Dronabinol is a synthetic form of ?9-THC,

Research and Development 52

Research and Development Pharmaceutical Chronic Pain Therapy 52

Canna Law Blog

MARCH 4, 2020

From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. major depressive disorder, post-traumatic stress disorder, acute suicidality).

Therapy 90

Therapy Legalization Chronic Pain DEA 90

Cannabis Law Report

AUGUST 2, 2021

Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. Key findings from the pre-clinical trial are as follows: SCI-160 significantly alleviates pain up to 6 hours after injection as compared with vehicle-treated animals. TEL AVIV, Israel , Aug. ” About The Study.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

CannaMD

NOVEMBER 8, 2019

VA providers can and do discuss marijuana use with veterans as part of comprehensive care planning, and adjust treatment plans as necessary. VA health care providers will record marijuana use in the veteran’s VA medical record in order to have the information available in treatment planning.

Marijuana 85

Marijuana Treatment Research and Development Patients 85